Moreover, the importance of PACSIN2 polymorphisms in the complications of thiopurine therapies may be context specific as it was shown that PACSIN2 polymorphism does not associate with the adverse effect of thiopurine when used for the treatment of inflammatory bowel disease.136. The gene discussed is PACSIN2; the disease is inflammatory bowel disease.